NCT00474539View on ClinicalTrials.gov

Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Vaccines, Pneumococcal
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

1 dose at 2,4,6 and 15 months of age

BIOLOGICAL

7-valent pneumococcal conjugate vaccine

1 dose at 2,4,6 and 15 months of age

Trial Locations (27)

4007

Almería

4009

Almería

4120

Almería

8195

Barcelona

8930

Barcelona

15270

A Coruña

15405

A Coruña

15706

Santiago de Compostela

28041

Madrid

28900

Madrid

28922

Madrid

28942

Madrid

29015

Málaga

29200

Málaga

31008

Pamplona

32005

Ourense

36204

Vigo

41013

Seville

46008

Valencia

46011

Valencia

46021

Valencia

46022

Valencia

46023

Valencia

46024

Valencia

46183

Valencia

46200

Valencia

46930

Valencia

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00474539 - Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants | Biotech Hunter | Biotech Hunter